Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21816817 | 0.85 | SMN1; SMN2 (0.39) | SMN1; SMN2GAAGRM5CNR2PRMT5 | |
| SCHEMBL15116671 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2GAAGRM5CNR2PRMT5 | |
| SCHEMBL21197563 | 0.83 | GAA (0.39) | SMN1; SMN2GAAGRM5CNR2PRMT5 | |
| SCHEMBL15531346 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2GAAGRM5CNR2PRMT5 | |
| SCHEMBL15114464 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2GAAGRM5CNR2PRMT5 | |
| Hydrochloric Acid SCHEMBL4247948 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2GAAGRM5CNR2PRMT5 | |
| SCHEMBL21565793 | 0.80 | GRIN2B (0.37) | SMN1; SMN2GAAGRM5CNR2PRMT5 | |
| SCHEMBL20671838 | 0.80 | ALDH1A1 (0.48) | SMN1; SMN2GAAGRM5CNR2PRMT5 | |
| SCHEMBL19341292 | 0.80 | PDE9A (0.39) | SMN1; SMN2GAAGRM5CNR2PRMT5 | |
| SCHEMBL20190860 | 0.80 | GRIN2B (0.39) | SMN1; SMN2GAAGRM5CNR2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| EP-3858832-A1 | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10647708-B2 | Tetrahydroisoquinoline derived PRMT5-inhibitors | CTXT PTY. LTD (AU) | 2020-05-12 | — | — | US | disclosed |
| WO-2019016385-A1 | BENZAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES | BASF SE (DE) | 2019-01-24 | — | — | WO | disclosed |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-11-02 | — | — | US | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-05 | — | — | US | disclosed |
| WO-2017153515-A1 | TETRAHYDROISOQUINOLINES AS PRMT5-INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153513-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153518-A1 | PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016034675-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034671-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | SMN1; SMN2 3457/4885CYP1A2 820/4885TDP1 1710/4885 |
| US-10647708-B2 | Tetrahydroisoquinoline derived PRMT5-inhibitors | PRMT5, PRMT3, PRMT1 | SMN1; SMN2 2617/4885CYP1A2 1990/4885TDP1 2159/4885 |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | SMN1; SMN2 2876/4885CYP1A2 1959/4885TDP1 2047/4885 |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | SMN1; SMN2 532/4885CYP1A2 749/4885TDP1 1782/4885 |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT3, PRMT1 | SMN1; SMN2 2617/4885CYP1A2 1990/4885TDP1 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.